People | June 17, 2022
Valo Therapeutics appoints Hemanshu Shah as Chief Business Officer
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Amarex Clinical Research guides its client to phase II of FDA trials
Centre of Excellence at Kharel comprises Skill-building Centre and Primary, Secondary and Higher Secondary schools
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
Subscribe To Our Newsletter & Stay Updated
